| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
N/A |
| Shares
Out: |
61,150,000 |
| Market
Cap: |
6.68(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$113.49 - $145.93 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Jazz Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing medicines for patients with serious diseases with limited or no options. Co.'s primary marketed products are: Xyrem® (sodium oxybate) oral solution, for the treatment of both cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Xywav™ (calcium, magnesium, potassium, and sodium oxybates) oral solution, for the treatment of cataplexy or EDS in narcolepsy patients seven years of age and older; and Sunosi® (solriamfetol), to improve wakefulness in adult patients with EDS associated with narcolepsy or obstructive sleep apnea.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
12,000 |
12,000 |
12,000 |
12,000 |
| Total Buy Value |
$1,435,800 |
$1,435,800 |
$1,435,800 |
$1,435,800 |
| Total People Bought |
1 |
1 |
1 |
1 |
| Total Buy Transactions |
1 |
1 |
1 |
1 |
| Total Shares Sold |
8,704 |
9,538 |
26,327 |
202,744 |
| Total Sell Value |
$986,699 |
$1,086,171 |
$3,399,099 |
$29,455,215 |
| Total People Sold |
2 |
4 |
12 |
19 |
| Total Sell Transactions |
3 |
5 |
21 |
74 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Berns Paul L |
Director |
– • – |
2020-08-07 |
4 |
S |
$125.87 |
$117,185 |
D/D |
(931) |
9,740 |
|
- |
|
| Okeefe Kenneth W |
Director |
– • – |
2020-08-07 |
4 |
S |
$125.87 |
$117,186 |
D/D |
(931) |
7,418 |
|
- |
|
| Mcsharry Heather Ann |
Director |
– • – |
2020-08-07 |
4 |
S |
$125.87 |
$127,003 |
D/D |
(1,009) |
10,333 |
|
- |
|
| Winningham Rick E |
Director |
– • – |
2020-08-07 |
4 |
S |
$125.87 |
$117,185 |
D/D |
(931) |
6,198 |
|
- |
|
| Riedel Norbert G |
Director |
– • – |
2020-08-07 |
4 |
S |
$125.87 |
$117,186 |
D/D |
(931) |
9,459 |
|
- |
|
| Gray Peter |
Director |
– • – |
2020-08-06 |
4 |
A |
$0.00 |
$0 |
D/D |
2,705 |
12,020 |
|
- |
|
| Sohn Catherine A. |
Director |
– • – |
2020-08-06 |
4 |
A |
$0.00 |
$0 |
D/D |
2,705 |
11,553 |
|
- |
|
| Schnee Elmar |
Director |
– • – |
2020-08-06 |
4 |
A |
$0.00 |
$0 |
D/D |
2,705 |
9,902 |
|
- |
|
| Mulligan Seamus |
Director |
– • – |
2020-08-06 |
4 |
A |
$0.00 |
$0 |
D/D |
2,705 |
1,155,493 |
|
- |
|
| Berns Paul L |
Director |
– • – |
2020-08-06 |
4 |
A |
$0.00 |
$0 |
D/D |
2,705 |
10,671 |
|
- |
|
| Okeefe Kenneth W |
Director |
– • – |
2020-08-06 |
4 |
A |
$0.00 |
$0 |
D/D |
2,705 |
8,349 |
|
- |
|
| Mcsharry Heather Ann |
Director |
– • – |
2020-08-06 |
4 |
A |
$0.00 |
$0 |
D/D |
2,705 |
11,342 |
|
- |
|
| Enright Patrick G |
Director |
– • – |
2020-08-06 |
4 |
A |
$0.00 |
$0 |
D/D |
2,705 |
20,368 |
|
- |
|
| Winningham Rick E |
Director |
– • – |
2020-08-06 |
4 |
A |
$0.00 |
$0 |
D/D |
2,705 |
7,129 |
|
- |
|
| Riedel Norbert G |
Director |
– • – |
2020-08-06 |
4 |
A |
$0.00 |
$0 |
D/D |
2,705 |
10,390 |
|
- |
|
| Oriordan Anne |
Director |
– • – |
2020-08-06 |
4 |
A |
$0.00 |
$0 |
D/D |
2,705 |
7,465 |
|
- |
|
| Sablich Kim |
EVP & GM, North America |
• – – |
2020-08-06 |
4 |
A |
$0.00 |
$0 |
D/D |
16,800 |
16,800 |
|
- |
|
| Patil Neena M |
SVP, General Counsel |
• – – |
2020-08-05 |
4 |
D |
$122.24 |
$120,651 |
D/D |
(987) |
19,489 |
|
- |
|
| Carr Patricia |
VP, Finance & PAO |
• – – |
2020-06-05 |
4 |
AS |
$124.00 |
$17,112 |
D/D |
(138) |
6,500 |
|
- |
|
| Iannone Robert |
EVP, Research & Development |
• – – |
2020-06-05 |
4 |
D |
$120.65 |
$113,773 |
D/D |
(943) |
22,204 |
|
- |
|
| Mulligan Seamus |
Director |
– • – |
2020-05-27 |
4 |
B |
$109.55 |
$3,894,058 |
D/D |
35,000 |
1,152,788 |
2.39 |
- |
|
| Mulligan Seamus |
Director |
– • – |
2020-05-26 |
4 |
B |
$110.65 |
$1,659,747 |
D/D |
15,000 |
1,117,788 |
2.39 |
- |
|
| Gala Renee D |
EVP & CFO |
• – – |
2020-05-07 |
4 |
A |
$0.00 |
$0 |
D/D |
16,600 |
16,600 |
|
- |
|
| Pearce Samantha |
SVP, Europe and Rest of World |
• – – |
2020-05-07 |
4 |
A |
$0.00 |
$0 |
D/D |
10,200 |
10,200 |
|
- |
|
| Miller Michael Patrick |
EVP, US Commercial |
• – – |
2020-03-12 |
4 |
AS |
$102.17 |
$153,255 |
D/D |
(1,500) |
22,118 |
|
- |
|
881 Records found
|
|
Page 13 of 36 |
|
|
0.37 (0.34%) 
